AB
ABUS.US Arbutus Biopharma Corp
- Market cap
- USD 627M
- P/E
- 3.7x
- P/B
- 6.95x
- ROE
- 347.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ABUS.US undervalued?
Graham numberABUS.US trades 6.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Arbutus Biopharma Corp fundamental analysis
No fundamental analysis for Arbutus Biopharma Corp yet.
Arbutus Biopharma Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has …
Full company profileArbutus Biopharma Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Arbutus Biopharma Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.50M | 10.7M | 5.90M | 6.01M | 6.91M | 11.0M | 39.0M | 18.1M | 6.17M | 14.1M | 241M |
| Gross Profit | -59.8M | -52.0M | -52.0M | -51.6M | -40.6M | 11.0M | 39.0M | 18.1M | 6.17M | 13.7M | 241M |
| Operating Income | -492M | -111M | -89.8M | -144M | -57.8M | -73.5M | -65.5M | -78.1M | -76.3M | -27.1M | 204M |
| EBITDA | -488M | -106M | -59.0M | -162M | -57.8M | -71.6M | -61.9M | -71.0M | -68.4M | -33.0M | 298M |
| Net Income | -384M | -84.4M | -57.1M | -154M | -63.7M | -76.2M | -69.5M | -72.8M | -69.9M | -33.5M | 298M |
| EPS | -7.24 | -1.54 | -1.03 | -2.69 | -0.84 | -0.72 | -0.46 | -0.44 | -0.38 | -0.17 | 1.49 |
| Balance Sheet | |||||||||||
| Total Assets | 276M | 237M | 228M | 106M | 137M | 204M | 195M | 144M | 132M | 94.6M | 340M |
| Total Liabilities | 72.9M | 54.7M | 27.7M | 32.8M | 35.1M | 35.0M | 58.6M | 38.4M | 34.3M | 18.0M | 254M |
| Shareholders' Equity | 203M | 183M | 200M | 72.7M | 102M | 169M | 137M | 106M | 97.4M | 76.6M | 85.7M |
| Cash & Short-term Investments | 131M | 126M | 125M | 90.8M | 123M | 155M | 147M | 126M | 123M | 91.5M | 337M |
| Total Debt | 18.7M | 18.0M | - | 3.36M | 22.5M | 18.9M | 12.6M | 8.72M | 6.12M | 4.19M | 328K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -57.9M | -48.6M | -67.9M | -71.0M | -51.4M | -67.5M | -35.4M | -85.9M | -64.9M | -39.6M | 301M |
| Capital Expenditure | 4.00M | 7.26M | 1.14M | 589K | 229K | 809K | 512K | 1.01M | 182K | 0.00 | 18.7M |
| Free Cash Flow | -61.9M | -55.9M | -69.0M | -71.6M | -51.7M | -68.3M | -35.9M | -86.9M | -65.0M | -39.6M | 301M |
| Ratios | |||||||||||
| ROE | -189.2% | -46.2% | -28.5% | -211.3% | -62.5% | -45.0% | -50.8% | -68.7% | -71.8% | -43.7% | 347.8% |
| ROA | -139.2% | -35.6% | -25.1% | -145.7% | -46.5% | -37.3% | -35.5% | -50.4% | -53.1% | -35.4% | 87.8% |
| Net Profit Margin | -25,606.7% | -788.8% | -967.8% | -2,557.4% | -922.0% | -693.9% | -178.0% | -401.6% | -1,133.0% | -237.9% | 124.0% |
| Debt to Equity | 0.09x | 0.10x | - | 0.05x | 0.22x | 0.11x | 0.09x | 0.08x | 0.06x | 0.05x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Arbutus Biopharma Corp dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 12.1M | 0.11 | - |
| 2020 | USD 12.1M | 0.16 | - |
| 2019 | USD 11.1M | 0.20 | - |
| 2018 | USD 10.1M | 0.18 | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:5 on Nov 4, 2010.
Who owns Arbutus Biopharma Corp
- Insiders 20.57%
- Institutions 79.43%
- Public & others 0.00%
- Shares outstanding 153M
- Free float 97.9M
Top funds holding ABUS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 5.03M | 3.28% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 3.97M | 2.59% | 0.00% | Oct 2026 |
| State Street® SPDR® S&P® Biotech ETF | 3.00M | 1.96% | +2.69% | Oct 2026 |
| Morgan Stanley Insight I | 2.73M | 1.78% | -28.82% | Jun 2026 |
| EQ/Morgan Stanley Small Cap Growth K | 1.79M | 1.17% | +30.66% | Sep 2026 |
| Fidelity Small Cap Index | 1.76M | 1.15% | 0.00% | Aug 2026 |
| Morgan Stanley Inst Inception I | 1.63M | 1.06% | -19.90% | Jun 2026 |
| iShares Russell 2000 Growth ETF | 1.52M | 0.99% | -0.38% | Oct 2026 |
| iShares Biotechnology ETF | 1.24M | 0.81% | -0.19% | Oct 2026 |
| Vanguard Russell 2000 ETF | 932K | 0.61% | +0.95% | Sep 2026 |
| Janus Henderson Small Cap Gr Alpha ETF | 929K | 0.61% | 0.00% | Oct 2026 |
| Fidelity Extended Market Index | 748K | 0.49% | -4.38% | Sep 2026 |
| MS INVF Global Insight Z | 656K | 0.43% | 0.00% | Jun 2026 |
| Schwab US Small-Cap ETF™ | 640K | 0.42% | +0.24% | Oct 2026 |
| Assenagon Funds Value Size Global RS | 621K | 0.41% | 0.00% | Sep 2026 |
| MS INVF Global Endurance Z USD Acc | 611K | 0.40% | +99.73% | Jun 2026 |
| Stt Strt®SPDR®S&PKenshoNwEcosComposETF | 537K | 0.35% | +0.08% | Oct 2026 |
| First Trust Dow Jones Sel MicroCap ETF | 529K | 0.35% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 503K | 0.33% | +27.00% | Sep 2026 |
| iShares Micro-Cap ETF | 488K | 0.32% | 0.00% | Oct 2026 |
Top institutions holding ABUS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Morgan Stanley - Brokerage Accounts | 17.7M | 11.55% | -31.64% | Jun 2026 |
| Whitefort Capital Management, LP. | 15.8M | 10.30% | +5.78% | Jun 2026 |
| BlackRock Inc | 13.8M | 8.98% | +6.16% | Jun 2026 |
| State Street Corp | 7.87M | 5.13% | +24.07% | Jun 2026 |
| Rubric Capital Management LP | 7.53M | 4.91% | +13.68% | Jun 2026 |
| Vanguard Capital Management, LLC | 7.01M | 4.57% | +4.81% | Jun 2026 |
| Barclays PLC | 4.21M | 2.75% | -2.51% | Jun 2026 |
| Geode Capital Management, LLC | 4.12M | 2.69% | +9.17% | Jun 2026 |
| The Goldman Sachs Group Inc | 3.51M | 2.29% | +218.67% | Jun 2026 |
| Bank of America Corp | 2.65M | 1.73% | +57.17% | Jun 2026 |
| BlackBarn Capital Partners LP | 2.50M | 1.63% | 0.00% | Jun 2026 |
| Legal & General Group PLC | 2.47M | 1.61% | +2.70% | Jun 2026 |
| Woodline Partners LP | 2.28M | 1.49% | +13.52% | Jun 2026 |
| Jefferies Financial Group Inc | 1.71M | 1.12% | -9.63% | Jun 2026 |
| Nomura Holdings Inc | 1.64M | 1.07% | 0.00% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.54M | 1.01% | +10.74% | Jun 2026 |
| Charles Schwab Investment Management Inc | 1.43M | 0.93% | +2.15% | Jun 2026 |
| Northern Trust Corp | 1.42M | 0.93% | +11.05% | Jun 2026 |
| Advisor Group Holdings, Inc. | 1.35M | 0.88% | -0.02% | Jun 2026 |
| ADAR1 Capital Management LLC | 1.27M | 0.83% | -59.53% | Jun 2026 |
Arbutus Biopharma Corp company profile
- Company name
- Arbutus Biopharma Corp
- Ticker
- ABUS.US
- ISIN
- CA03879J1003
- Exchange
- USA Stocks
- Listed since
- Aug 3, 2015
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 19
- Fiscal year end
- December
- Address
- 701 Veterans Circle, Warminster, PA, United States, 18974
- Phone
- 267 469 0914
- Website
- arbutusbio.com
About Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Arbutus Biopharma Corp management
4- Ms. Lindsay Androski J.D., M.B.A.President, CEO & Chairman · born 1977
- Mr. Tuan NguyenChief Financial Officer · born 1976
- Mr. Andrew J. SungGeneral Counsel
- Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C.Corporate Secretary · born 1951